Chronic Migraine Headache

Neurology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Vedanta Biosciences
Vedanta BiosciencesMA - Cambridge
1 program
1
liquid embolic agent SQUID 12, liquid embolic agent SQUID 18Phase 11 trial
Active Trials
NCT06848166Recruiting30Est. May 2027

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
Vedanta Biosciencesliquid embolic agent SQUID 12, liquid embolic agent SQUID 18

Clinical Trials (1)

Total enrollment: 30 patients across 1 trials

NCT06848166Vedanta Biosciencesliquid embolic agent SQUID 12, liquid embolic agent SQUID 18

Study of the Effectiveness and Safety of Embolization of the Middle Meningeal Artery Using Non-adhesive Materials SQUID 12 and SQUID 18 in the Treatment of Patients With Chronic Resistant Migraine

Start: Oct 2024Est. completion: May 202730 patients
Phase 1Recruiting

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 30 patients
1 companies competing in this space